Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Over the last 12 months, insiders at Boston Scientific Corporation have bought $0 and sold $60.77M worth of Boston Scientific Corporation stock.
On average, over the past 5 years, insiders at Boston Scientific Corporation have bought $2.1M and sold $66.86M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $2.1M was made by WICHMANN DAVID S (director) on 2021‑11‑15.
2024-06-03 | Sale | Carruthers Wendy | EVP, Human Resources | 6,983 0.0005% | $75.33 | $526,029 | +1.91% | |
2024-05-29 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 63,802 0.0043% | $75.10 | $4.79M | +2.34% | |
2024-05-28 | Sale | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 14,011 0.001% | $75.34 | $1.06M | +2.04% | |
2024-05-23 | Sale | Brennan Daniel J. | EVP and CFO | 47,621 0.0033% | $75.11 | $3.58M | +2.59% | |
2024-05-22 | Sale | Brennan Daniel J. | EVP and CFO | 64,454 0.0044% | $75.91 | $4.89M | +1.17% | |
2024-05-22 | Sale | Brown Vance R | SVP, GC and Corp. Secretary | 15,006 0.001% | $76.01 | $1.14M | +1.17% | |
2024-05-21 | Sale | Brown Vance R | SVP, GC and Corp. Secretary | 18,037 0.0012% | $75.60 | $1.36M | +0.66% | |
2024-05-10 | Sale | Thepaut Eric Francis Yves | EVP & Pres, Eur, Mid-East, Afr | 12,931 0.0009% | $74.14 | $958,717 | +2.87% | |
2024-05-07 | Sale | Dockendorff Charles J | director | 3,946 0.0003% | $72.70 | $286,874 | +3.00% | |
2024-05-01 | Sale | Sorenson John Bradley | EVP, Global Operations | 17,587 0.0012% | $71.50 | $1.26M | +4.58% | |
2024-05-01 | Sale | Carruthers Wendy | EVP, Human Resources | 6,983 0.0005% | $71.47 | $499,075 | +4.58% | |
2024-04-26 | Sale | LUDWIG EDWARD J | director | 9,818 0.0007% | $73.29 | $719,562 | +3.00% | |
2024-04-01 | Sale | Carruthers Wendy | EVP, Human Resources | 6,983 0.0005% | $68.42 | $477,777 | +8.19% | |
2024-04-01 | Sale | Sorenson John Bradley | EVP, Global Operations | 16,351 0.0011% | $69.30 | $1.13M | +8.19% | |
2024-03-18 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 14,506 0.001% | $66.45 | $963,930 | +8.61% | |
2024-03-01 | Sale | Carruthers Wendy | EVP, Human Resources | 6,983 0.0005% | $66.35 | $463,322 | +8.00% | |
2024-02-26 | Sale | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 9,335 0.0006% | $67.07 | $626,098 | +8.04% | |
2024-02-23 | Sale | Carruthers Wendy | EVP, Human Resources | 6,983 0.0005% | $66.89 | $467,093 | +7.40% | |
2024-02-21 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 4,960 0.0003% | $66.35 | $329,096 | +7.12% | |
2024-02-20 | Sale | Brennan Daniel J. | EVP and CFO | 13,662 0.0009% | $65.86 | $899,779 | +4.15% |
Mahoney Michael F | Chairman, President & CEO | 1498922 0.1023% | $77.10 | 2 | 22 | +37.05% |
Brennan Daniel J. | EVP and CFO | 223921 0.0154% | $77.10 | 0 | 23 | |
Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 173472 0.0118% | $77.10 | 0 | 17 | |
Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 28022 0.0039% | $77.10 | 0 | 43 | |
Carruthers Wendy | EVP, Human Resources | 45628 0.0028% | $77.10 | 0 | 40 | |
Sorenson John Bradley | EVP, Global Operations | 50638 0.0023% | $77.10 | 0 | 26 | |
Brown Vance R | SVP, GC and Corp. Secretary | 32326 0.002% | $77.10 | 0 | 3 | |
LUDWIG EDWARD J | director | 41374 0.0008% | $77.10 | 1 | 2 | +26.95% |
Thepaut Eric Francis Yves | EVP & Pres, Eur, Mid-East, Afr | 31422 0.0008% | $77.10 | 0 | 13 | |
Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 20197 0.0005% | $77.10 | 0 | 16 | |
Dockendorff Charles J | director | 0 0.0003% | $77.10 | 1 | 2 | +35.4% |
NICHOLAS PETER M | director | 3531021 0.241% | $77.10 | 0 | 249 | |
ABELE JOHN E | Director Emeritus | 500000 0.0341% | $77.10 | 5 | 212 | +7.41% |
Bose Supratim | EVP & President, Asia-Pacific | 320301 0.0219% | $77.10 | 0 | 2 | |
BEST LAWRENCE C | EVP | 232189 0.0158% | $77.10 | 1 | 24 | <0.0001% |
NICHOLAS NJ JR | director | 225000 0.0154% | $77.10 | 20 | 1 | +2.99% |
Nanavaty Maulik | SVP & Pres, Neuromodulation | 166869 0.0114% | $77.10 | 0 | 22 | |
Pratt Timothy A. | EVP, GC & Chief Admin Officer | 154681 0.0106% | $77.10 | 0 | 32 | |
ELLIOTT JOHN RAYMOND | director | 118264 0.0081% | $77.10 | 1 | 0 | <0.0001% |
Kucheman William | Chief Executive Officer | 112525 0.0077% | $77.10 | 3 | 1 | +27.04% |
Phalen Michael P. | EVP & President, MedSurg | 97910 0.0067% | $77.10 | 0 | 38 | |
Lance Jean Fitterer | SVP, Asst GC, Bus & Regions | 97504 0.0067% | $77.10 | 0 | 10 | |
MARIO ERNEST | director | 86032 0.0059% | $77.10 | 22 | 18 | +4.5% |
Ballinger Kevin J. | EVP & Pres, Interven Cardio | 80085 0.0055% | $77.10 | 0 | 25 | |
Wang Xin Warren | SVP and Pres, Asia Pacific | 75469 0.0052% | $77.10 | 0 | 4 | |
Dawkins Keith D | EVP, Global Chief Med. Off. | 68165 0.0047% | $77.10 | 0 | 4 | |
PEPPER JOHN E | director | 58807 0.004% | $77.10 | 3 | 0 | <0.0001% |
Pucel Kenneth | EVP, Glob Ops, Qual & Tech | 59000 0.004% | $77.10 | 0 | 1 | |
TOBIN JAMES R | President and CEO | 50000 0.0034% | $77.10 | 0 | 2 | |
LAVIOLETTE PAUL A | COO | 49422 0.0034% | $77.10 | 0 | 5 | |
MCCONNELL WILLIAM F JR | SVP, Administration CRM | 48949 0.0033% | $77.10 | 0 | 2 | |
Prange Karen | SVP&Pres, Uro & Pelvic Health | 38395 0.0026% | $77.10 | 0 | 6 | |
MACLEAN ROBERT G | SVP, HR | 36502 0.0025% | $77.10 | 0 | 10 | |
Monson Jonathan | SVP, Global Controller and CAO | 34868 0.0024% | $77.10 | 0 | 5 | |
SANDMAN PAUL W | EVP and General Counsel | 33866 0.0023% | $77.10 | 0 | 4 | |
Sununu John E | director | 32265 0.0022% | $77.10 | 3 | 4 | +4.31% |
Bartlett Katharine T | director | 29708 0.002% | $77.10 | 1 | 0 | +4.24% |
Meredith Ian T | EVP Global Chief Med Officer | 28082 0.0019% | $77.10 | 0 | 2 | |
Connors Nelda J | director | 27246 0.0019% | $77.10 | 1 | 4 | <0.0001% |
WICHMANN DAVID S | director | 25000 0.0017% | $77.10 | 1 | 0 | +0.3% |
Mackey Edward F | EVP, Operations | 23722 0.0016% | $77.10 | 0 | 3 | |
Eddy Jodi Euerle | SVP, Chief Info & Digital Off. | 23263 0.0016% | $77.10 | 0 | 8 | |
Scanlon Meghan | SVP,Pres,Urology Pelvic Health | 19142 0.0013% | $77.10 | 0 | 2 | |
FLEISHMAN JOEL LAWRENCE | director | 18250 0.0012% | $77.10 | 1 | 0 | +1.14% |
Olson Scott | SVP & Pres, CRM, Diagnostics | 14518 0.001% | $77.10 | 0 | 6 | |
BURNS URSULA M | director | 13500 0.0009% | $77.10 | 4 | 0 | <0.0001% |
Ralls-Morrison Desiree | SVP, GC and Corp Secretary | 11450 0.0008% | $77.10 | 0 | 3 | |
TAYLOR JAMES H JR | Sr. VP, Operations | 9360 0.0006% | $77.10 | 0 | 4 | |
MORECI STEPHEN F | SVP, Global Sales Operations | 7216 0.0005% | $77.10 | 1 | 7 | <0.0001% |
REINHARDT UWE E | director | 5000 0.0003% | $77.10 | 3 | 1 | <0.0001% |
Goodman Jeffrey H | SVP, International | 5000 0.0003% | $77.10 | 2 | 0 | <0.0001% |
FOX MARYE ANNE | director | 3305 0.0002% | $77.10 | 1 | 0 | +18.63% |
GROVES RAY J | director | 1000 0.0001% | $77.10 | 3 | 0 | <0.0001% |
Burns Brian R | EVP - Global Quality & Reg Aff | 1289 0.0001% | $77.10 | 0 | 1 | |
BARTELL MARK C | SVP Global Sales/Mkt CRM | 1812 0.0001% | $77.10 | 0 | 1 | |
COLEN FRED | EVP & Chief Technology Officer | 0 0% | $77.10 | 0 | 18 | |
Pierce David A | EVP Pres MedSurg | 0 0% | $77.10 | 0 | 88 | |
Russell Mary E | SVP and CMO | 0 0% | $77.10 | 0 | 2 | |
Pedersen John B. | Pres, Uro & Women's Health | 0 0% | $77.10 | 0 | 3 | |
CAPELLO JEFFREY D | EVP & Chief Financial Officer | 447 0% | $77.10 | 0 | 5 | |
DEPARLE NANCY ANN | director | 0 0% | $77.10 | 0 | 2 | |
FUJIMORI YOSHIAKI | director | 0 0% | $77.10 | 0 | 1 | |
JOHNSON KRISTINA M | director | 0 0% | $77.10 | 0 | 3 |
Fidelity Investments | $9.72B | 9.65 | 141.93M | +2.66% | +$251.98M | 0.65 | |
The Vanguard Group | $8.73B | 8.67 | 127.44M | +1.58% | +$136.16M | 0.17 | |
BlackRock | $8.69B | 8.63 | 126.84M | +0.22% | +$18.9M | 0.2 | |
State Street | $4.3B | 4.27 | 62.73M | +0.63% | +$26.96M | 0.19 | |
Massachusetts Financial Services Co Ma | $3.19B | 3.17 | 46.61M | -18.48% | -$723.87M | 0.95 | |
PRIMECAP Management Co | $2.6B | 2.58 | 37.95M | +0.11% | +$2.88M | 1.96 | |
Wellington Management Company | $2.28B | 2.26 | 33.29M | -8.65% | -$215.9M | 0.39 | |
JPMorgan Chase | $2.16B | 2.14 | 31.48M | +9.94% | +$194.92M | 0.19 | |
Bank of America | $2.05B | 2.04 | 29.96M | +6.45% | +$124.28M | 0.2 | |
Geode Capital Management | $1.94B | 1.94 | 28.45M | +3.25% | +$61.22M | 0.17 | |
The Bollard Group | $1.51B | 1.5 | 22M | -1.75% | -$26.91M | 45.73 | |
Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $1.41B | 1.4 | 20.62M | -2.41% | -$34.83M | 1.6 | |
Janus Henderson | $1.27B | 1.27 | 18.61M | -4.31% | -$57.42M | 0.7 | |
Morgan Stanley | $1.23B | 1.22 | 17.96M | -4.25% | -$54.57M | 0.1 | |
Artisan Partners | $1.11B | 1.1 | 16.18M | -5.78% | -$67.97M | 1.63 | |
Capital World Investors | $1.1B | 1.09 | 16.01M | +69.94% | +$451.23M | 0.18 | |
Franklin Templeton Investments | $1.07B | 1.07 | 15.68M | +929.91% | +$969.43M | 0.32 | |
BNY Mellon | $1.06B | 1.05 | 15.47M | -8.82% | -$102.54M | 0.2 | |
Goldman Sachs | $1B | 1 | 14.67M | -8.49% | -$93.15M | 0.19 | |
Legal & General | $920.46M | 0.91 | 13.44M | -0.63% | -$5.81M | 0.22 | |
Northern Trust | $894.41M | 0.89 | 13.06M | -4.97% | -$46.78M | 0.15 | |
Invesco | $863.06M | 0.86 | 12.6M | +0.43% | +$3.66M | 0.18 | |
Nuveen | $818.93M | 0.81 | 11.96M | +15.53% | +$110.1M | 0.24 | |
Amundi | $747.36M | 0.75 | 11.09M | -19.06% | -$176M | 0.31 | |
Vontobel Asset Management Inc | $728.45M | 0.68 | 9.98M | -9.04% | -$72.36M | 4.04 | |
Millennium Management LLC | $615.02M | 0.65 | 9.48M | +28.66% | +$136.98M | 0.44 | |
Citadel Advisors LLC | $600.94M | 0.6 | 8.77M | -2.31% | -$14.21M | 0.39 | |
Voya Investment Management LLC | $575.02M | 0.57 | 8.4M | +20.96% | +$99.64M | 0.65 | |
Canada Pension Plan Investment Board | $540.88M | 0.54 | 7.9M | +14.96% | +$70.38M | 0.55 | |
Charles Schwab | $540.55M | 0.54 | 7.89M | +2.57% | +$13.54M | 0.12 | |
UBS | $532.74M | 0.53 | 7.78M | +10.31% | +$49.77M | 0.16 | |
LAZARD ASSET MANAGEMENT LLC | $508.87M | 0.51 | 7.43M | -15.84% | -$95.78M | 0.67 | |
Ubs Asset Management Americas Inc | $501.58M | 0.5 | 7.32M | -7.82% | -$42.56M | 0.18 | |
T. Rowe Price | $491.91M | 0.49 | 7.18M | +13.94% | +$60.16M | 0.06 | |
Ameriprise Financial | $416.08M | 0.41 | 6.08M | -19.26% | -$99.27M | 0.12 | |
Holocene Advisors, LP | $396.42M | 0.39 | 5.79M | -26.6% | -$143.63M | 1.47 | |
Fil Ltd | $384.17M | 0.38 | 5.61M | -5.65% | -$22.99M | 0.38 | |
Bank of Montreal | $355.29M | 0.35 | 5.17M | -1.46% | -$5.25M | 0.11 | |
Arrowstreet Capital, Limited Partnership | $335.73M | 0.33 | 4.9M | -18.95% | -$78.49M | 0.31 | |
Agf Management Ltd | $332.48M | 0.33 | 4.85M | -0.09% | -$304,164.09 | 1.87 | |
Winslow Capital Management Llc | $331.92M | 0.33 | 4.85M | -3.73% | -$12.86M | 1.25 | |
Dimensional Fund Advisors | $317.52M | 0.32 | 4.64M | +2.36% | +$7.33M | 0.09 | |
Farallon Capital | $314.83M | 0.31 | 4.6M | -21.02% | -$83.8M | 2.2 | |
SEI Investments Company | $313.2M | 0.31 | 4.57M | -0.07% | -$211,839.45 | 0.47 | |
Impax Asset Management Group | $305.1M | 0.3 | 4.47M | +2.83% | +$8.41M | 1.17 | |
Investec Asset Management UK | $301.29M | 0.3 | 4.4M | -1.12% | -$3.4M | 0.85 | |
Swiss National Bank | $300.48M | 0.3 | 4.39M | -4.18% | -$13.12M | 0.21 | |
Deutsche Bank | $298.51M | 0.3 | 4.36M | +7.45% | +$20.7M | 0.14 | |
Royal Bank of Canada | $295.4M | 0.29 | 4.31M | -1.28% | -$3.82M | 0.07 | |
Barclays | $277.15M | 0.28 | 4.05M | +19.91% | +$46.01M | 0.13 |